C4 Therapeutics (CCCC) Accounts Payables (2019 - 2026)

C4 Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $773000.0 for Q1 2026.

• In Q1 2026, Accounts Payables rose 13.18% year-over-year to $773000.0; the TTM figure through Mar 2026 stood at $773000.0 (up 13.18% YoY), while the FY2025 annual figure was $858000.0, down 35.39% from the prior year.
• Accounts Payables was $773000.0 for Q1 2026 at C4 Therapeutics, down from $858000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.4 million in Q2 2022 to a low of $683000.0 in Q1 2025.
• Historically, Accounts Payables has averaged $1.7 million across 5 years, with a median of $1.3 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables sank 73.99% in 2022, then soared 142.72% in 2025.
• A 5-year view of Accounts Payables shows it stood at $1.2 million in 2022, then increased by 23.38% to $1.4 million in 2023, then retreated by 8.16% to $1.3 million in 2024, then slumped by 35.39% to $858000.0 in 2025, then slipped by 9.91% to $773000.0 in 2026.
• The last three Accounts Payables figures came in at $773000.0 (Q1 2026), $858000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.